Everest Medicines Limited

SZSC:1952 Stock Report

Market Cap: HK$15.6b

Everest Medicines Management

Management criteria checks 2/4

Everest Medicines' CEO is Rogers Luo, appointed in Sep 2022, has a tenure of 2.33 years. total yearly compensation is CN¥30.72M, comprised of 23.5% salary and 76.5% bonuses, including company stock and options. directly owns 0.3% of the company’s shares, worth HK$47.41M. The average tenure of the management team and the board of directors is 2.6 years and 3.3 years respectively.

Key information

Rogers Luo

Chief executive officer

CN¥30.7m

Total compensation

CEO salary percentage23.5%
CEO tenure2.3yrs
CEO ownership0.3%
Management average tenure2.6yrs
Board average tenure3.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Rogers Luo's remuneration changed compared to Everest Medicines's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-CN¥1b

Mar 31 2024n/an/a

-CN¥949m

Dec 31 2023CN¥31mCN¥7m

-CN¥844m

Sep 30 2023n/an/a

-CN¥424m

Jun 30 2023n/an/a

-CN¥3m

Mar 31 2023n/an/a

-CN¥125m

Dec 31 2022CN¥8mCN¥2m

-CN¥247m

Compensation vs Market: Rogers's total compensation ($USD4.20M) is above average for companies of similar size in the Hong Kong market ($USD545.23K).

Compensation vs Earnings: Rogers's compensation has increased whilst the company is unprofitable.

CEO

Rogers Luo (54 yo)

2.3yrs

Tenure

CN¥30,722,000

Compensation

Mr. Yongqing Luo, also known as Rogers, is CEO & Executive Director of Everest Medicines Limited from September 19, 2022. He was President and General Manager of Greater China at Brii Biosciences Limited a...

Leadership Team

NamePositionTenureCompensationOwnership
Fu Wei
Executive Chairman7.5yrsno data0.59%
HK$ 92.3m
Yongqing Luo
CEO & Executive Director2.3yrsCN¥30.72m0.30%
HK$ 47.4m
Ian Ying Woo
CFO, President & Executive Director6.6yrsCN¥18.46m0.063%
HK$ 9.8m
Jason M. Brown
Chief Business Officer5.4yrsno datano data
Wei Yang
Chief Scientific Officer3.8yrsno datano data
Steve Xu
Chief Legal & Compliance Officerless than a yearno datano data
Rico Liang
Chief Product Officerless than a yearno datano data
Sandra Zeng
Chief Medical Officerless than a yearno datano data
Yee Wa Lau
Joint Company Secretaryno datano datano data
Leah Liu
Joint Company Secretary & VP of Corporate Affairs2.8yrsno datano data

2.6yrs

Average Tenure

51yo

Average Age

Experienced Management: 1952's management team is considered experienced (2.6 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Fu Wei
Executive Chairman7.5yrsno data0.59%
HK$ 92.3m
Yongqing Luo
CEO & Executive Director2.3yrsCN¥30.72m0.30%
HK$ 47.4m
Ian Ying Woo
CFO, President & Executive Director6.1yrsCN¥18.46m0.063%
HK$ 9.8m
Yifan Li
Independent Non-Executive Director4.3yrsCN¥401.00kno data
Ki Chul Cho
Non-Executive Directorless than a yearno datano data
Shidong Jiang
Independent Non-Executive Director4.3yrsCN¥401.00kno data
Hoi Yam Chui
Independent Non-Executive Director2yrsCN¥352.00kno data
Honggang Feng
Non-Executive Directorless than a yearno datano data

3.3yrs

Average Tenure

54.5yo

Average Age

Experienced Board: 1952's board of directors are considered experienced (3.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/04 08:38
End of Day Share Price 2025/01/03 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Everest Medicines Limited is covered by 13 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Bo LiBofA Global Research
Ziyu HeChina International Capital Corporation Limited
Jin ZhangChina International Capital Corporation Limited